Yumi Emoto, Satofumi Iida, Hidenobu Aso, Haruki Kinoshita
Evaluation of Population PK/PD for Osteoporosis during a Vitamin D3 (1,25(OH)2D3) Derivative Therapy
|
Mike Dunlavey
Simplified programming of population model user interfaces
|
F T Musuamba (1), J L Bosmans(2), J J Senessael (3), J Cumps (1), P Wallemacq (4) and R K Verbeeck (1)
Limited sampling formulas and bayesian estimation for mycophenolic acid 12 hours Area Under the concentration-time Curve prediction in Stable renal transplant recipients co-medicated with cyclosporine or sirolimus
|
Rogier R. Press
Optimizing Calcineurin Inhibitor Exposure In De Novo Kidney Transplant Recipients
|
J. Smeets(1), B. Ploeger(1), A. Strougo(1), L. Liefaard(1), T. Kerbusch(2)
A Mechanism-based Pharmacokinetic Model Describing the Interaction Between Sugammadex and Rocuronium in Patients with Normal and Impaired Renal Function
|
Susan Willavize
Dose Selection for Combination Drug Products
|
Susan Willavize(1) , Ruolun Qiu (1), Marc Gastonguay (2)
Using M&S to Shorten the Repeating Cycle of the Early Drug Development Process: A Case Study
|
Mariska Y.M. Peeters(1), Karel Allegaert(2), Heleen Blussé van Oud-Alblas(3,4), Massimo Cella(5), Dick Tibboel(4), Meindert Danhof(5), Catherijne A.J. Knibbe(1,4,5)
Predictive Value of Allometric Scaling for Estimation of Propofol Clearance in Neonates, Infants and Adolescents
|
Elke H.J. Krekels1,2, Gijs W.E. Santen1, John N. van den Anker2,3, Joost de Jongh1,4, Evelyne M. Jacqz-Aigrain5, Caroline D. van der Marel2,6, Richard A. van Lingen7, Anne M. Lynn8, Monique van Dijk2, Sinno Simons2, Meindert Danhof1, Dick Tibboel2, Catherijne A.J. Knibbe1,2,9
Development AND External validation of a model for Glucuronidation in children below 3 years of age using morphine as a model drug; towards a novel dosing paradigm.
|
Emmanuelle Comets (1), Sarah Zohar (2,3)
Modelling is seldom used to describe pharmacokinetics in phase I clinical trials
|
Johan E Wallin (1), Lena E Friberg (1), Christine E Staatz (2)
Population pharmacokinetics of tacrolimus in paediatric heamatopeitic stem cell transplantation
|
Pascal Chanu (1), Bruno Reigner (1), Nathalie Schultze (1), Ronald Gieschke (1), Nicolas Frey (1)
Decisive support of Modeling & Simulation for getting drug approval in the context of safety concern on the drug class
|
G. Morrish(1), C.Kirkpatrick(1), N. Byrne(2), H. Kinoshita(3) & B. Green(1)
Using Body Composition Metrics to Predict Exposure Between Japanese and Caucasian Populations
|
Tamara van Steeg, Ashley Strougo, Bart Ploeger and Piet Hein van der Graaf
Assessment of the use of complex baseline models in preclinical safety screening: Application of the van der Pol oscillator model to describe heart rate effects in rats
|
S. Fanta(1), S. Jönsson(2), M.O. Karlsson(3), C. Holmberg(4), K. Hoppu(1), J.T. Backman(1)
Population Pharmacokinetics of Cyclosporine in Paediatric Renal Transplant Recipients
|
C. Chen (1), A. MacDonald (1)
Population PK/PD modelling of functional receptor occupancy in a first-time-in human study
|
C. Becker(1), K. Coboeken(1), L. Kuepfer(1), J. Lippert(1), R. Nubbemeyer(2), H. Blode(2)
Whole-Body Physiologically-based Pharmacokinetic (WB-PBPK) Population Modelling to Simulate the Influence of Weight and Age on the Pharmacokinetics (PK) of a combined Oral Contraceptive Containing Drospirenone (DRSP) and Ethinylestradiol (EE)
|
Estelle Watson, Daniël M. Jonker, Steen H. Ingwersen
The pharmacokinetics of the once-daily human glucagon-like peptide-1 analogue, liraglutide, across 5 trials in healthy subjects and type 2 diabetics after single and multiple dosing
|
